View Older Stories View More Recent Stories

Nov 7, 2017 08:26AM Regeneron (REGN) and Sanofi (SNY) to Present New Analyses from Praluent Injection ODYSSEY Clinical Trial Program at AHA
Nov 7, 2017 08:00AM Regeneron and Sanofi to Present New Analyses from the Praluent® (alirocumab) Injection ODYSSEY Clinical Trial Program at the AHA Scientific Sessions 2017
Nov 1, 2017 09:00AM Regeneron to Share Clinical Progress of REGN1979 and Cemiplimab (REGN2810) in B-Cell Lymphomas at the 2017 ASH Annual Meeting
Oct 31, 2017 07:14AM Sanofi (SNY) Says Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 31, 2017 07:00AM Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 31, 2017 06:58AM Sanofi : Dupilumab Significantly Reduced Steroid Use, Asthma Attacks, and Improved Lung Function in a Phase 3 Study of People with Severe Steroid-Dependent Asthma
Oct 27, 2017 07:00AM Regeneron's First Global Day of Service Supports Over 100 Non-Profit and Community Organizations
Oct 19, 2017 02:30PM Science Magazine Ranks Regeneron #1 Biopharma Employer for Fifth Time
Oct 16, 2017 08:06AM Sanofi (SNY), Regeneron (REGN) Phase 2 Study Results for Dupilumab Shows Significant Improvement Versus Placebo
Oct 16, 2017 08:01AM Sanofi and Regeneron Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 16, 2017 08:00AM Regeneron and Sanofi Announce Positive Phase 2 Study Results for Dupilumab in Patients With Active Moderate-to-Severe Eosinophilic Esophagitis
Oct 11, 2017 09:30AM Regeneron to Report Third Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on November 8, 2017
Oct 11, 2017 08:00AM Internationally Acclaimed Writer and Executive Producer of HBO's The Night Of Reveals His Personal Story Detailing the Harsh Realities of Atopic Dermatitis
Oct 5, 2017 12:33PM Sanofi (SNY) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:31PM Regeneron (REGN) Confirms Appellate Court Ordered New Trial and Vacated Permanent Injunction in Patent Case Regarding Praluent
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:30PM Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 5, 2017 12:29PM Sanofi : Appellate Court Orders a New Trial and Vacates Permanent Injunction in Ongoing Patent Case Regarding Praluent® (alirocumab)
Oct 2, 2017 07:02AM Regeneron (REGN) Reports New Collaborations with HHS & BARDA to Develop New Treatments Against Ebola, Influenza and Multiple Other Emerging Pathogens
Oct 2, 2017 07:00AM Regeneron Announces New Collaborations with HHS to Develop Antibodies Against Ebola, Influenza and Multiple Other Emerging Pathogens
Sep 28, 2017 05:56AM Sanofi (SNY) & Regeneron (REGN) Report Approval of Dupixent (Dupilumab) in European Union to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Sep 28, 2017 01:00AM Sanofi and Regeneron Announce Approval of Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 28, 2017 01:00AM Regeneron and Sanofi Announce Approval of DUPIXENT® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis in the European Union
Sep 18, 2017 05:40AM Sanofi (SNY) & Regeneron Pharmaceuticals (REGN) Report Positive Study Results for Dupixent (Dupilumab)
Sep 16, 2017 02:15AM Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 16, 2017 02:15AM Regeneron and Sanofi Announce Positive Study Results for DUPIXENT® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis
Sep 11, 2017 06:12AM Regeneron (REGN) & Sanofi (SNY) Report Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 01:00AM Regeneron and Sanofi Announce Positive Dupilumab Topline Results from Phase 3 Trial in Uncontrolled Persistent Asthma
Sep 11, 2017 12:58AM Sanofi, Regeneron: Dupilumab Hits Main Objectives in Late-Stage Asthma Trial
Sep 8, 2017 05:41AM Regeneron (REGN) & Sanofi (SNY) Granted FDA Breakthrough Designation for Cemiplimab (REGN2810), Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 01:00AM Regeneron and Sanofi Announce Cemiplimab (REGN2810) Has Received FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma
Sep 8, 2017 12:58AM Sanofi, Regeneron: Cemiplimab Receives FDA Breakthrough Designation for Advanced Cutaneous Squamous Cell Carcinoma
Aug 31, 2017 04:01PM Regeneron Announces Upcoming Investor Conference Presentations
Aug 25, 2017 08:00AM Regeneron and Sanofi to Present New Analyses from Praluent® (alirocumab) Injection Trials at the ESC Congress 2017
Aug 14, 2017 09:06AM Regeneron to Discontinue Development of Suptavumab for Respiratory Syncytial Virus
Aug 3, 2017 08:22AM Accessing the Regeneron Second Quarter 2017 Financial and Operating Results Webcast
Aug 3, 2017 06:30AM Regeneron Reports Second Quarter 2017 Financial and Operating Results
Jul 21, 2017 07:32AM Sanofi (SNY) and Regeneron (REGN) Receive Positive CHMP Opinion for Dupixent to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Sanofi and Regeneron Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 21, 2017 07:30AM Regeneron and Sanofi Receive Positive CHMP Opinion for Dupixent® (dupilumab) to Treat Adult Patients with Moderate-to-Severe Atopic Dermatitis
Jul 13, 2017 09:30AM Regeneron to Report Second Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on August 3, 2017
Jul 13, 2017 08:30AM Regeneron Announces the 2017 Winners of the Regeneron Prize for Creative Innovation
Jun 27, 2017 05:47AM Sanofi (SNY) & Regeneron (REGN) Granted EU Marketing Approval from Kevzara (sarilumab) in Combination with Methotrexate
Jun 27, 2017 01:00AM Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 27, 2017 01:00AM Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union
Jun 22, 2017 09:01AM Regeneron (REGN) Details Royalty Agreement with Novartis for ACZ885
Jun 22, 2017 09:00AM Regeneron Details Royalty Agreement with Novartis for Canakinumab (ACZ885)
Jun 21, 2017 08:30AM Regeneron Recognized on "The Civic 50" List of the Most Community-Minded Companies in the United States
Jun 19, 2017 07:08AM Veeva Systems (VEEV) Reports 99% of Clinical Operations Leaders Report the Need to Unify Their Clinical Applications; Regeneron Pharmaceuticals (REGN) Standardizing on Veeva Vault Submissions
Jun 19, 2017 07:03AM Standardizing on Veeva Vault Enhances Regeneron’s Clinical and Regulatory Operations Processes
View More Recent Stories View Older Stories